Navigation Links
Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
Date:6/22/2013

lt;0.001) for empagliflozin 10 mg (n=225) and 25 mg (n=216), respectively, compared with placebo (n=225).2 The study also showed statistically significant placebo-adjusted reductions at 24 weeks in mean daily glucose concentration of 10.02 mg/dL and 13.06 mg/dL (p<0.001) with empagliflozin 10 mg and 25 mg., respectively. Reductions in body weight were significantly greater with the addition of empagliflozin to metformin plus sulfonylurea (change in body weight of 3.88 lbs, 10 mg; and 4.39 lbs, 25mg; p<0.001).2

Drug-related adverse events were reported by 24.1 percent, 19.8 percent and 15.1 percent of patients on empagliflozin 10 mg, empagliflozin 25 mg, and placebo, respectively. Confirmed hypoglycemia was reported in 16.1 percent of patients on empagliflozin 10 mg, 11.5 percent on empagliflozin 25 mg and 8.4 percent on placebo, none of which required assistance. Adverse events consistent with urinary tract infection were reported in 10.3 percent of patients on empagliflozin 10 mg, 8.3 percent on empagliflozin 25 mg and 8.0 percent on placebo. Adverse events consistent with genital infection were reported in 2.7 percent of patients on empagliflozin 10 mg, 2.3 percent on empagliflozin 25 mg and 0.9 percent on placebo.

About the Empagliflozin Phase III Clinical Trial Program
Empagliflozin is being investigated in adults with T2D in a phase III clinical trial program that has enrolled more than 14,500 patients. This program includes more than 10 multinational clinical trials, including a large cardiovascular outcomes trial.

About Diabetes
Approximately 25.8 million Americans3 and an estimated 371 million people worldwide4 have type 1 or type 2 diabetes. T2D is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases.3 Diabetes is a chronic condition that occurs when the body does not properly produce or use the hormone insulin.5 Diab
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Amgen (NASDAQ: AMGN ) announced that ... share dividend for the third quarter of 2015. The ... all stockholders of record as of the close of ... Amgen Amgen is committed to unlocking the potential of ... developing, manufacturing and delivering innovative human therapeutics. This approach ...
(Date:7/28/2015)... 2015   Regulus Therapeutics Inc . ( NASDAQ: ... development of innovative medicines targeting microRNAs, today announced that ... quarter ended June 30, 2015 on Tuesday, August 4, ... Regulus will host a conference call and webcast ... Daylight Time to discuss its second quarter 2015 financial ...
(Date:7/28/2015)... July 28, 2015 On the afternoon of ... company of CPI International, Inc. (CPI), plans to file ... 3, 2015 with the Securities and Exchange Commission and ... the quarter.  At 11 a.m. (EDT) on Wednesday, August ... in conjunction with this release that will be Web ...
Breaking Medicine Technology:Amgen Announces 2015 Third Quarter Dividend 2Amgen Announces 2015 Third Quarter Dividend 3Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 3CPI International To Announce Third Quarter 2015 Financial Results 2
... PARK, N.C. & GENEVA--(BUSINESS WIRE)--Jul 11,2007 ... research and,development program for Plasmin (Human), ... this week at the XXIst International,Society ... in Geneva,Switzerland. The information included new ...
... WIRE)--Jul 11, 2007 - BioSante,Pharmaceuticals, Inc. (Amex: ... its calcium phosphate (CaP),nanoparticle-based vaccine adjuvant, BioVant(TM), ... the development of a dose sparing,vaccine against ... flu., The new results are based on ...
Cached Medicine Technology:New Information on the Potential of Plasmin Shared at ISTH Congress 2New Information on the Potential of Plasmin Shared at ISTH Congress 3New Information on the Potential of Plasmin Shared at ISTH Congress 4BioSante Pharmaceuticals Announces New Findings for Potential Bird,Flu Vaccine 2BioSante Pharmaceuticals Announces New Findings for Potential Bird,Flu Vaccine 3BioSante Pharmaceuticals Announces New Findings for Potential Bird,Flu Vaccine 4
(Date:7/29/2015)... ... 2015 , ... One of the world’s leading experts on ... lifesaving impact of removing aluminum from Alzheimer’s disease patients, announced the Children’s ... on a successful pilot study published in The Journal of Alzheimer’s Disease in ...
(Date:7/29/2015)... ... July 29, 2015 , ... ITW ... oversees. In her role, Powers is responsible for driving growth and innovation across ... commented, “Gina’s track record as an effective leader within the ITW community speaks ...
(Date:7/28/2015)... ... ... City Sports, a specialty sports retailer and a premiere destination for dedicated ... , Hanaka, who has served on the Board of Directors for City Sports since ... Fund has had previous tenures as Chairman and CEO of Golfsmith International Holdings, Inc., ...
(Date:7/28/2015)... ... 28, 2015 , ... The Memorial Cardiac and Vascular Institute ... expert, streamlined total advanced heart care for the South Florida community. , The ... one roof, including the treatment of advanced heart failure, adult heart transplant, left ...
(Date:7/28/2015)... ... July 28, 2015 , ... Mindful Her, a unique ... to take their healthy and mindful living practices to the next level, announced today ... of Living with Intent as keynote. Global Girls, an Orange County based non-profit ...
Breaking Medicine News(10 mins):Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 2Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 3Health News:Gina Powers Named Vice President & General Manager of ITW Dynatec 2Health News:Gina Powers Named Vice President & General Manager of ITW Dynatec 3Health News:City Sports Names Marty Hanaka CEO 2Health News:Memorial Cardiac And Vascular Institute Centralizes Cardiac Care Through It's New "Total Heart Center" At Memorial Regional Hospital 2Health News:Women’s Healthy Living Event Mindful Her Set for October 24, 2015 in Orange County 2Health News:Women’s Healthy Living Event Mindful Her Set for October 24, 2015 in Orange County 3
... and it was the prime consideration when a team of ... lives. The Baby Bubbler or in its ... helps children with acute respiratory infections breathe naturally as ... percent of deaths in children under 5 are caused by ...
... The prevalence of mild sleep-disordered breathing in young ... will be presented Monday, June 7, 2010, in San ... of the Associated Professional Sleep Societies LLC. Results ... mild sleep-disordered breathing in elementary-school children increased steadily from ...
... build up a big sweat to reap the healing ... a low-intense exercise program can reduce depression symptoms and ... "The power of physical activity to raise the ... suspected," Heart and Stroke Foundation researcher Dr. Jocelyn Harris ...
... are uncommon as children enter adolescence, parasomnias present in ... a research abstract that will be presented Monday, June ... the 24th annual meeting of the Associated Professional Sleep ... persistence after five years was 29 percent for children ...
... professor in the department of biochemistry and organic chemistry ... this year,s recipient of the Georg Charles de Hevesy ... medicine profession. Lngstrm was presented the award by SNMan ... June 5𔃇, in Salt Lake City, Utah. ...
... undergoing treatment for melanoma that has spread to the ... the liver,s blood vessels, according to a study sponsored ... and led by James F. Pingpank, M.D., associate professor ... surgical oncologist with UPMC Cancer Centers. The results will ...
Cached Medicine News:Health News:Baby Bubbler a breath of fresh air 2Health News:Study finds a seasonal variance in sleep-disordered breathing in young children 2Health News:Non-intense physical activity to reduce depression and boost recovery of stroke patients 2Health News:Non-intense physical activity to reduce depression and boost recovery of stroke patients 3Health News:Childhood parasomnias such as sleepwalking and bedwetting may persist into adolescence 2Health News:Bengt Roland Långström receives SNM's 2010 Georg Charles de Hevesy Nuclear Pioneer Award 2Health News:New treatment method safe, effective for advanced melanoma patients 2
The 6.5mm cannulated cancellous ACE SCFE Screw is specifically designed for the treatment of slipped capital femoral epiphysis. The ACE SCFE Screw simplifies insertion and facilitates removal....
The DePuy ACE 8.0mm Cannulated Cancellous Screw incorporates TiMAX to provide superior strength, fatigue resistance and a lower modulus of elasticity when compared to similar stainless steel devices....
Smith & Nephew offers a wide variety of cannulated screw products. Most screw sizes are available in both partially threaded and fully threaded versions. , ,All systems optimize implant strength with...
Biomet® Arthrodesis Nail indications include: , Failed external fixation , Aseptic failed total knee arthroplasty , Periarticular fractures where repair is not possible , Limb salvage in tumor...
Medicine Products: